What is the appropriate workup and initial management for a 38-year-old man with a two‑week history of dyspnea on exertion, hemoglobin 17.1 g/dL, platelet count 737 ×10⁹/L, and triglycerides 368 mg/dL?

Workup and Management for 38-Year-Old Male with Dyspnea, Elevated Hemoglobin, Thrombocytosis, and Hypertriglyceridemia

This patient requires immediate evaluation for a myeloproliferative neoplasm (MPN), specifically polycythemia vera or essential thrombocythemia, given the constellation of elevated hemoglobin (17.1 g/dL), marked thrombocytosis (737 ×10⁹/L), and dyspnea on exertion in a young male.

Initial Diagnostic Approach

Immediate Laboratory Workup

The combination of erythrocytosis (Hgb 17.1) and thrombocytosis (platelets 737) in a 38-year-old male is highly suspicious for an MPN. You need:

• JAK2 V617F mutation testing (present in >95% of polycythemia vera cases)
• Complete blood count with differential to assess for leukocytosis
• Peripheral blood smear to evaluate cell morphology
• Serum erythropoietin level (will be low in polycythemia vera)
• Comprehensive metabolic panel including LDH and uric acid (often elevated in MPNs)
• Oxygen saturation at rest and with exertion to exclude secondary polycythemia from hypoxemia

Cardiovascular Evaluation for Dyspnea

Given the dyspnea on exertion, you must systematically exclude cardiac causes 1, 2:

• Chest radiograph as first-line imaging 2
• Electrocardiogram to assess for ischemia, arrhythmia, or chamber enlargement 1
• Brain natriuretic peptide (BNP) to help exclude heart failure 1
• Echocardiography if initial screening suggests cardiac etiology 3, 4

If initial tests are nondiagnostic, proceed to cardiopulmonary exercise testing (CPET) 1, 5. CPET can differentiate between cardiovascular oxygen delivery problems, peripheral muscle oxygen utilization issues, and ventilatory disorders. This is particularly valuable in unexplained dyspnea 1.

Pulmonary Assessment

• Spirometry to exclude obstructive or restrictive lung disease 6, 7
• CT chest without contrast if chest X-ray is abnormal or clinical suspicion remains high despite normal radiograph 2

Critical Clinical Considerations

Why MPN is the Priority Diagnosis

The thrombocytosis (737 ×10⁹/L) combined with elevated hemoglobin creates a hypercoagulable state with increased thrombotic risk. Research demonstrates that patients with severe hypertriglyceridemia and thrombocytosis have increased platelet activation 8, 9, further elevating cardiovascular risk. The dyspnea could represent:

1. Pulmonary microvascular thrombosis from the hypercoagulable state
2. Hyperviscosity syndrome from elevated red cell mass
3. Pulmonary hypertension (evaluate with echocardiography if suspected) 10
4. Cardiac ischemia from increased blood viscosity and oxygen demand

Hypertriglyceridemia Management

The triglycerides at 368 mg/dL represent borderline high elevation 11. While not the primary concern here:

• Evaluate for secondary causes: poorly controlled diabetes, hypothyroidism, alcohol use, medications (thiazides, beta-blockers, estrogens)
• Therapeutic lifestyle modifications are first-line 11
• Statin therapy should be initiated for ASCVD risk reduction 11
• Consider icosapent ethyl if patient has established ASCVD or diabetes with elevated cardiovascular risk on maximally tolerated statin 11

Immediate Management Algorithm

If MPN is Confirmed:

1. Urgent hematology referral for definitive diagnosis and risk stratification
2. Aspirin 81-100 mg daily (unless contraindicated) to reduce thrombotic risk
3. Phlebotomy if polycythemia vera confirmed, targeting hematocrit <45% in males
4. Cytoreductive therapy (hydroxyurea) may be needed based on risk stratification
5. Aggressive cardiovascular risk factor modification including triglyceride management

If MPN is Excluded:

Follow the unexplained dyspnea algorithm 1:

• Proceed to CPET with echocardiography 5 to identify mechanisms
• Pattern recognition from CPET guides further testing:
  • Abnormal O₂ delivery/utilization → cardiac imaging, possible catheterization
  • Abnormal gas exchange → pulmonary imaging, bronchoscopy
  • Chronotropic incompetence → exercise stress testing, Holter monitoring

Common Pitfalls to Avoid

• Do not dismiss the thrombocytosis as reactive without excluding MPN—reactive thrombocytosis rarely exceeds 700 ×10⁹/L
• Do not attribute dyspnea solely to deconditioning in a 38-year-old without objective testing
• Do not delay hematology evaluation while pursuing extensive cardiac workup—the MPN itself may be causing the dyspnea
• Do not overlook secondary polycythemia causes: sleep apnea, chronic hypoxemia, testosterone use, smoking history
• Recognize that multiple mechanisms may coexist 5—patients with unexplained dyspnea average 1.5-2.3 concurrent mechanisms

The elevated hemoglobin and marked thrombocytosis in a young patient with new dyspnea demands urgent evaluation for MPN, as this represents a potentially life-threatening condition requiring immediate intervention to prevent thrombotic complications.